What the Afrezza TV commercial - Mealtime is about.
The Afrezza TV Spot, 'Mealtime' is a commercial that features a person who suffers from diabetes. The commercial begins with the person talking about how they have to take insulin before each meal, which can be inconvenient and embarrassing. The actor then introduces Afrezza, a new insulin delivery system that eliminates the need for injections.
Through the commercial, the viewer learns about the benefits of Afrezza, such as its speed of action and the ability to use it discreetly in public. We see the person going about their daily routine, taking Afrezza just before eating to help regulate their blood sugar levels. The viewer also hears from doctors who recommend the product and praise its effectiveness.
The commercial effectively highlights the advantages of Afrezza and how it can help make life easier for those who suffer from diabetes. The use of real actors and doctors adds credibility to the product, and the message is delivered in a clear and concise way that is easy for the viewer to understand. Overall, the Afrezza TV Spot, 'Mealtime' is an informative and compelling commercial that effectively promotes the product and its benefits.
Afrezza TV commercial - Mealtime produced for
Afrezza
was first shown on television on June 25, 2018.
Frequently Asked Questions about afrezza tv spot, 'mealtime'
1-877-323-8505. What are the ingredients in AFREZZA? Active ingredient: human insulin Inactive ingredients: fumaryl diketopiperazine, polysorbate 80 This Medication Guide has been approved by the U.S. Food and Drug Administration.
Mechanism of Action
When the insulin is inhaled through the device, the powder is aerosolized and delivered to the lung. Insulin lowers blood glucose levels by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Afrezza® is not for use in people with chronic lung disease such as asthma and COPD. It is not known if Afrezza® is safe and effective for use in people who smoke. Afrezza® is not for use in people who smoke or have recently stopped smoking (less than 6 months).
Danbury, Connecticut
Afrezza was developed by MannKind Corporation, and continues to be manufactured at the company's headquarters in Danbury, Connecticut.
Afrezza® is an ultra rapid-acting mealtime insulin that is breathed in through your lungs using an oral inhaler. Afrezza® gives you the flexibility to eat when you want while providing proven blood sugar control.
Afrezza Coupons, Prices, and Savings Card
Inhaled insulin powder is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Learn more about Afrezza inhalation . This is a brand name drug and a generic may be available. The average cost for 1 Box, 90 powder each, is $533.99.
Enjoy the benefits of Afrezza®'s ultra rapid-action whenever it's time to eat, even if it's unexpected. Is inhaled insulin safe? Afrezza® inhaled insulin is safe, effective and FDA approved. The most common side effects are: low blood sugar (hypoglycemia), cough, and sore throat.
- August 11, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for ...
MEALTIME INSULIN: Insulin that you take just before you eat a meal. It is a rapid-acting (bolus, or mealtime) type of insulin and is usually taken in addition to a long-acting (basal, or background) insulin. BASAL/BACKGROUND INSULIN COMES IN TWO FORMS: Long-acting insulin and intermediate-acting insulin.
You'll need 1 unit of fast-acting insulin to adjust to your target of 120. If you plan to eat a meal that has 60 grams of carbohydrates, you'll need to give yourself 6 units of insulin to adjust for your meal. This means you'll need 7 units total.
Throw the insulin away 28 days after opening it. Once you open a vial, keep it stored in the fridge or at room temperature. Be aware that injecting refrigerated insulin may be painful. Keep an insulin pen refrigerated until you open it; after that, you can store it at room temperature.
On June 27, 2014, the US Food and Drug Administration approved Afrezza (MannKind, Danbury, CT), an ultra-rapid-acting inhaled insulin to improve postprandial glycemic control in adults with diabetes mellitus.
